High frequency of Candida fabianii among clinical isolates biochemically identified as Candida pelliculosa and Candida utilis

Mycoses
L SvobodovaPetr Hamal

Abstract

Clinical yeast isolates belonging to Candida pelliculosa, Candida utilis and Candida fabianii are difficult to distinguish in a routine mycology laboratory using common biochemical tests. The aims of this study were to determine the prevalence of C. pelliculosa, C. utilis and C. fabianii in clinical samples and to compare their minimum inhibitory concentrations (MICs) to systemic antifungals. Two hundred and forty-eight clinical yeast isolates obtained from eight large hospitals in the Czech Republic were included in this study. Identification was performed biochemically using ID 32C kit and by MALDI-TOF MS. MICs were determined using colorimetric broth dilution Sensititre YeastOne panels. From a total number of 248 isolates, 175 were identified as C. pelliculosa and 73 as C. utilis using the biochemical kit. In contrast, MALDI-TOF MS identified 222 isolates as C. fabianii, 20 as C. pelliculosa and 6 as C. utilis. The highest mean MICs were found in C. fabianii and, regardless of the studied species, in isolates from blood cultures and central venous catheters. MALDI-TOF MS revealed C. fabianii to be most prevalent in clinical samples as compared with the other studied species. Higher MIC values in C. fabianii support the impor...Continue Reading

References

May 1, 1990·The Journal of Infectious Diseases·D P DooleyB S Jeffery
Feb 24, 2001·Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·S W ReddingT F Patterson
May 17, 2002·The Journal of Hospital Infection·V Krcmery, A J Barnes
Aug 12, 2003·International Journal of Radiation Oncology, Biology, Physics·Marta C DahiyaCharles R Thomas
Dec 23, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M DendisJ Benedík
Aug 27, 2005·The Journal of Antimicrobial Chemotherapy·Malcolm D Richardson
Jun 21, 2006·Mycoses·Giuseppe ValenzaOliver Kurzai
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jennifer K ChowSusan Hadley
Sep 9, 2008·Mycoses·Christian TraederKeikawus Arastéh
Feb 2, 2010·The Pediatric Infectious Disease Journal·Frédéric GrenouilletJoel Leroy
Apr 27, 2010·Food Microbiology·Sheila Romo-SánchezAna Briones-Pérez
Jun 16, 2011·Medical Mycology·Frederic GabrielIsabelle Accoceberry
Mar 12, 2013·Journal of Medical Microbiology·Jae Won YunNam Yong Lee
Mar 21, 2013·BMC Research Notes·Yuan WuYing Cheng
Jan 21, 2014·World Journal of Microbiology & Biotechnology·Savitree LimtongHiroko Kawasaki

❮ Previous
Next ❯

Citations

Nov 26, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Veronika OpletalovaMarta Kucerova-Chlupacova
Mar 14, 2017·EFSA Journal·UNKNOWN EFSA Panel on Biological Hazards (BIOHAZ)Pablo Salvador Fernández Escámez
Jan 22, 2021·The Journal of International Medical Research·Zeyu CaiZhongle Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.